Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Curie-Cancer and Vygon Sign a Partnership Agreement Extension

Published: Tuesday, April 16, 2013
Last Updated: Tuesday, April 16, 2013
Bookmark and Share
The Curie-Cancer and Vygon partnership will extend over several years and will achieve the development of catheters and implantable ports with increased resistance to nosocomial infections, for launch on the international market.

Curie-Cancer and Vygon have announced their partnership to develop a new generation of innovative medical devices; mainly for use in chemotherapy. The partnership aims to introduce them to European, the US and Asian markets.

Chemotherapy treatments for cancer are generally administered intravenously, using implantable ports (small reservoirs that are surgically implanted beneath the skin).

Injected or infused liquid passes through the port via a catheter that is connected to the port at one end, with the other end inserted into a large thoracic vein in proximity to the heart.

These reservoirs have a thick silicone membrane that is punctured each time a course of chemotherapy is administered. They can be left in place for several months if required by the duration of a treatment.

Unfortunately, as with any regularly accessed implanted medical device, these implantable ports present a risk of infection. This may have serious consequences for patients whose immune defenses are compromised as a result of chemotherapy.

Although this type of infection is quite rare, doctors at the Institut Curie are keen to have implantable ports that carry an even lower risk of infection.

Vygon, a world leader in this field, is looking to offer its clients a range of products with greater infection resistance than those available on the market.

Curie-Cancer and Vygon have agreed to design implantable ports that address these requirements, using technology developed by the Institut Curie.

An initial partnership agreement was signed in 2010, with each party contributing their expertise and part of the necessary resources.

“The members of my team worked collaboratively to develop more resistant implantable ports in response to a genuine demand from caregivers, with regular interaction with Vincent Semetey, a physical chemist at the Institut Curie and Marc Esteve, director of the anesthesiology department at the Institut Curie and an expert in implantable ports, ” said Jean-Luc Carrez, R&D director at Vygon.

After a very positive three-year initial partnership, the two partners are committing to an extension of their arrangement.

This will support the final stages of the work that will bring the new range of products to the international market using Vygon's international influence.

“As a medium-sized business it is not always easy to access academic innovation. However, it is something that we need to do in order to remain competitive on the international market,” said Stephane Regnault, chairman of Vygon's board of management.

Regnault continued, ‘In Curie-Cancer, we have found a trusted partner who has shared our aims right from the start. Without a doubt, this is one of the main reasons why our organizations have such a productive relationship and why we are delighted to continue working together.”

The partners have decided to embark on a new partnership agreement focusing on a new technology. This will see them explore new approaches and share the risks inherent in this type of exploration, which has much more in common with basic research than with applied research.

“We are looking forward to contributing to the development of a mid-sized French company such as Vygon, while also exploring new approaches to medical devices. This project encapsulates the Institute's primary aim of providing practical solutions for industry and ultimately, for patients,” said Damien Salauze, director of Curie-Cancer.

Salauze continued, “It is clear once again that the expertise developed at the Institut Curie for the purpose of basic research also addresses the requirements expressed by our industry partners.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Curie-Cancer and DNA Therapeutics Partner in the Fight Against Cancers
Their clinical and translational research program has developed Dbait molecules now in Phase I clinical trial in patients with advanced melanoma.
Thursday, March 06, 2014
Curie-Cancer and Servier Continue a Renewed Partnership in Cancer Research
Their joint aim is to identify new therapeutic targets in ‘triple negative’ breast cancers.
Wednesday, January 29, 2014
Curie-Cancer and Sanofi Cooperate in Research on Ovarian Cancer
Preclinical program of translational research tasked with identifying new target proteins.
Wednesday, June 19, 2013
Curie-Cancer and Biolog-id Sign Partnership Agreement
Within the partnership, Curie-Cancer and Biolog-id will develop a pilot system of RFID tags suitable for use in tracking cancer chemotherapy preparations.
Wednesday, June 05, 2013
Curie-Cancer and Roche Strengthen Partnership
Curie-Cancer and Roche build on four years partnership by increasing translational research programs, speeding up development of new cancer treatments.
Friday, May 17, 2013
Curie-Cancer and GenoSplice Technology Sign Bioinformatics Partnership Agreement
The innovative partnership is planned to run for several years to develop unique, high value added genomic approaches.
Wednesday, January 30, 2013
Curie-Cancer Funds its First Selection of Five Late-Stage Projects
Funding of these first five projects enables Institut Curie’s discoveries to progress more rapidly to the industrial stage, making innovation available to patients more quickly.
Friday, December 14, 2012
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!